Can tirzepatide stop working — and what does the evidence say?

What the SURMOUNT-1 trial tells us about plateaus

The clearest evidence on tirzepatide's long-term trajectory comes from the SURMOUNT-1 trial, published in the New England Journal of Medicine, which followed adults with obesity for 72 weeks. Weight loss did not continue at the same rate throughout. The steepest reduction happened in the first 24 to 36 weeks; after that, the curve flattened as participants approached a new biological equilibrium. At 15mg, average total body-weight reduction reached around 20–21%, but the final months contributed far less loss than the first.

This flattening is not tirzepatide losing efficacy. It reflects a well-understood physiological reality: as body weight falls, so does resting metabolic rate, and the body requires less energy to maintain its new lower mass. The medicine continues suppressing appetite and slowing gastric emptying, but the arithmetic of energy balance shifts. A plateau on the scale during active treatment is a very different situation from tirzepatide not working at all. Our prescribers hear some version of this question most weeks, and the answer almost always begins with that distinction.

The extension phase of SURMOUNT-1 (where a group stopped the medicine after 36 weeks) reinforced this. Within a year of stopping, participants regained roughly two-thirds of the weight they had lost. Their appetite returned, gastric emptying normalised, and the hormonal signals that tirzepatide had been modulating reasserted themselves. The weight regain was not dramatic in the short term, but it was steady. That pattern is consistent with how GLP-1 and GIP receptor agonism works: the benefit is tied to continued treatment.

Does tirzepatide stop working more at certain doses?

Dose is a real variable. Tirzepatide's licensed schedule in the UK starts at 2.5mg, a tolerability step, not a therapeutic ceiling. The clinical programme tested doses up to 15mg, and the weight-loss benefit was clearly dose-dependent: higher doses produced greater average reductions. If someone is at 5mg or 7.5mg and loss has stalled, that is not necessarily the medicine plateauing; it may be that the current dose is where their physiology sits comfortably, and titration upward (when clinically appropriate and reviewed by a prescriber) could renew progress.

It is also worth knowing that tirzepatide's effectiveness over time is influenced by factors outside the medicine itself. Significant changes in diet, activity, sleep, stress levels, or the addition of other medicines can all shift the balance, and if you are taking hormonal contraception alongside treatment, it is worth reading about whether Mounjaro affects how well the pill works. So can conditions that affect metabolism. None of this means tirzepatide has stopped working; it means the context around it has changed, and the prescriber's job is to unpick which factor is driving the change.

For anyone wondering whether a stall is normal or whether something else is going on, a detailed look at why tirzepatide may not be working as expected covers the common clinical explanations. The short version: a genuine plateau after months of steady loss is far more likely than true drug failure.

What 'does tirzepatide stop working' usually means clinically

The phrase gets used for at least three distinct situations, and they need separating. The first is a plateau during active treatment at the right dose, almost always a metabolic adaptation, not a failure. The second is a slower-than-expected start, often because the person is still on the 2.5mg or 5mg starter phases and titration simply hasn't reached an effective level yet. The third is post-treatment weight regain, which the SURMOUNT extension data makes clear is a predictable consequence of stopping rather than evidence that the medicine was ever ineffective.

There is a fourth, rarer situation: a genuine non-response, where weight loss remains below 5% after six months at the highest tolerated dose. NICE's appraisal of tirzepatide (TA1026) notes that continuing treatment should be reviewed if this threshold is not reached. This is exactly the kind of assessment a prescriber handles at a repeat review. Stopping the medicine is one clinical option; adjusting the approach, reviewing adherence, or investigating an underlying factor are others.

If you are considering stopping tirzepatide rather than adjusting it, it helps to understand what that process looks like. Stopping tirzepatide is a clinical decision with real implications for appetite regulation and weight trajectory, not something to do abruptly without a conversation. The full clinical profile of tirzepatide in the UK covers its mechanism, schedule, and what to expect across the treatment period.

For a broader look at how this plays out with the branded UK product, Mounjaro and a stalled response explores the same question through a practical lens. And if you are wondering whether the medicine is right for you at all, our treatment overview sets out what clinically supervised weight management actually involves. One transparent consultation is where that starts, there is no obligation, and a real prescriber reviews every case.

If you have questions before you begin, our FAQs cover the most common ones. Ready to discuss your situation with a prescriber? Start your free consultation and a GPhC-registered Independent Prescriber will review your case the same day.